Media Coverage

An ancient animal's blood is a modern medical miracle

06/17/2014

At a facility on the outskirts of Charleston, South Carolina, Charles River Endosafe® extracts the blood from horseshoe crabs. Charles River is one of four companies in the US that utilize horseshoe crabs’ blood to manufacture Limulus Amebocyte Lysate (LAL), which is used for the detection and quantification of bacterial endotoxins.

Protecting an Ancient Mariner

06/09/2014

Limulus amebocyte lysate (LAL), a reagent that utilizes clotting enzymes extracted from horseshoe crab blood, is among the most accurate and reliable indicators of bacteria. Charles River continues to serve as an advocate for the optimal usage of LAL and conservation of this creature.

Five Ways to Improve Host-Cell Protein Assay Performance

05/02/2014

Arguably, the biggest challenge in making biologics is flagging unwanted host-cell proteins (HCPs) that inevitably show up in the finished product. While nano in scale, these trace amounts can be highly immunogenic and can ultimately sink a potential biopharmaceutical. As a result, manufacturers must work hard to identify and control any impurities in the final product.

What Charles River Labs' recent buys say about the future of biotech

03/14/2014

The area’s largest preclinical research organization just got a little larger with the acquisition of two European firms. But what CEO Jim Foster said about the reason for the acquisitions says a lot about both contract research organizations and where biotech in general is headed.

Charles River buys 2 firms in bid to strengthen R&D

03/14/2014

Charles River Laboratories International Inc. announced it will pay $179 million to buy a pair of European drug-targeting businesses that will help it expand its capabilities as a contract research organization for pharmaceutical and biotechnology companies.

Charles River Aims To Be One-Stop Shop With Buyout

03/13/2014

Today, Charles River Laboratories (CRL) announced that it has agreed to buy the CRO business of Belgian drugmaker Galapagos NV. This acquisition will enable Charles River to offer a full suite of discovery and early stage capabilities, positioning itself as a one-stop shop for biopharma customers.

Displaying results 1-10 (of 49)
 |<  < 1 - 2 - 3 - 4 - 5  >  >|